IKT News and Press, Inhibikase Therapeutics Inc.

WILMINGTON, Del., April 07, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that the ...

2025-08-15 06:38:19 ET More on Inhibikase Therapeutics Seeking Alpha’s Quant Rating on Inhibikase Therapeutics Historical earnings data for Inhibikase Therapeutics Financial information for Inhibikase Therapeutics Read the full article on Seeking Alp...

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hy...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

Inhibikase Therapeutics Inc. (IKT) is expected to report $-0.09 for Q2 2025

2025-08-12 18:45:12 ET Inhibikase Therapeutics, Inc. (IKT) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 8.00%. The average open to low on the day of earnings was -7.14%. The average o...

2025-08-12 18:40:09 ET Inhibikase Therapeutics, Inc. (IKT) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in IKT stock price following earnings has averaged ±2.77% , with a median of 2.0...

2025-06-20 17:12:33 ET More on Inhibikase Therapeutics Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise Read the full article on Seeking Alpha For further details see: Inhi...

2025-05-15 11:56:29 ET More on Inhibikase Therapeutics Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise Seeking Alpha’s Quant Rating on Inhibikase Therapeutics Historica...

BOSTON and ATLANTA, May 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension ( ...